Etifoxine

Etifoxine (6-chloro-N-ethyl-4-methyl-4-phenyl-4H-3,1-benzoxazin-2-amine) is a non-benzodiazepine anxiolytic of the benzoxazine structural class, first synthesized by Hoechst AG in 1966 and introduced for clinical use in France in 1979 under the trade name Stresam. The compound is marketed in approximately 40 countries for the treatment of anxiety disorders, principally adjustment disorders with anxiety, but has not been approved by the United States Food and Drug Administration or by the European Medicines Agency for centralized marketing authorization across the European Union. Etifoxine is pharmacologically distinguished from both the benzodiazepine class and from other non-benzodiazepine anxiolytics (buspirone, hydroxyzine) by a dual mechanism of action at the GABAergic system. The first mechanism is direct positive allosteric modulation of the GABAA receptor through binding at the beta subunit, with preferential potentiation of receptors containing beta2 or beta3 subunits, at a site distinct from the benzodiazepine binding site located at the alpha/gamma interface. The second mechanism is binding to the 18 kDa translocator protein (TSPO, formerly the peripheral benzodiazepine receptor) on the outer mitochondrial membrane, which stimulates the translocation of cholesterol into the mitochondrial matrix and the subsequent biosynthesis of endogenous neurosteroids, principally pregnenolone, progesterone, 5-alpha-dihydroprogesterone, and allopregnanolone. Allopregnanolone is itself a potent positive allosteric modulator of the GABAA receptor at the neurosteroid binding site (distinct from both the benzodiazepine and the etifoxine direct binding sites), producing a convergent, temporally extended potentiation of GABAergic inhibitory neurotransmission. This dual mechanism produces anxiolytic efficacy comparable to benzodiazepines in clinical trials of adjustment disorder with anxiety, with significantly reduced incidence of sedation, psychomotor impairment, amnesia, rebound anxiety on withdrawal, and physical dependence. Pharmacokinetics are characterized by rapid oral absorption, high bioavailability (approximately 90 percent), hepatic metabolism to an active metabolite (diethyl-etifoxine) with a half-life of approximately 20 hours, and predominant renal excretion. The clinical evidence base includes multiple randomized controlled trials comparing etifoxine to lorazepam, alprazolam, and placebo in adjustment disorder with anxiety, with the AMETIS study (a three-arm trial versus lorazepam and placebo) producing a notable negative result in which neither active arm separated from placebo. The compound has an established clinical safety profile over more than 40 years of marketed use, with rare but serious adverse events including severe cutaneous reactions (drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, erythema multiforme) and hepatotoxicity (acute cytolytic hepatitis), which prompted a 2021 European Medicines Agency Article 31 referral concluded in January 2022 with continued marketing authorization subject to contraindication in patients with prior severe dermatological or hepatic reactions. Beyond the anxiolytic indication, etifoxine has generated a substantial preclinical research literature in neuroprotection following peripheral nerve injury, traumatic brain injury, experimental autoimmune encephalomyelitis (a model of multiple sclerosis), and neuropathic pain, with the neuroprotective activity attributed to TSPO-mediated neurosteroidogenesis and downstream anti-inflammatory and neurotrophic effects. A deuterated analog, GRX-917 (GABA Therapeutics, a subsidiary of atai Life Sciences), has completed Phase 1 clinical trials with improved pharmacokinetic properties and is in development for anxiety and related disorders. This monograph reviews the chemistry, synthesis, and structural classification of etifoxine; the dual-receptor mechanism in molecular and electrophysiological detail; the comprehensive pharmacokinetic record; the preclinical pharmacology across neuroprotection, nerve injury, traumatic brain injury, and pain models; the clinical evidence base in anxiety disorders; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal including the EMA referral outcome; and a comparative assessment of five anxiolytic alternatives against etifoxine on five competency standards.